

Regulus Therapeutics Inc.  
Form SC TO-I/A  
November 09, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**SCHEDULE TO**  
**(Amendment No. 1)**  
**(Rule 13e-4)**  
**Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)**  
**of the Securities Exchange Act of 1934**

**Regulus Therapeutics Inc.**  
**(Name of Subject Company (Issuer) and Filing Person (Offeror))**

**Options to Purchase Common Stock, \$0.001 Par Value Per Share**  
**(Title of Class of Securities)**

**75915K 200**  
**(CUSIP Number of Common Stock Underlying Class of Securities)**

**Joseph P. Hagan**  
**President and Chief Executive Officer**

**Regulus Therapeutics Inc.**

**10614 Science Center Drive**

**San Diego, CA 92121**

**(858) 202-6300**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications On Behalf of Filing Person)**

*Copies to*

**Thomas A. Coll, Esq.**

**Kenneth J. Rollins, Esq.**

**Cooley LLP**

**4401 Eastgate Mall**

**San Diego, California 92121**

**(858) 550-6000**

**CALCULATION OF FILING FEE**

**Transaction Valuation\***

\$711,382

**Amount of Filing Fee\*\***

\$86.22

\* Estimated solely for purposes of calculating the amount of the filing fee. The calculation of the Transaction Valuation assumes that all stock options to purchase shares of the issuer's common stock that may be eligible for exchange in the offer will be tendered pursuant to this offer. These stock options covered an aggregate of 915,009 shares of the issuer's common stock, and had an aggregate value of \$711,382 as of October 12, 2018, calculated based on a Black-Scholes option pricing model.

\*\* The amount of the filing fee, calculated in accordance with Rule 0-11(b) of the Securities Exchange Act of 1934, as amended, equals \$121.20 per \$1,000,000 of the aggregate amount of the Transaction Valuation (or 0.01212% of the aggregate Transaction Valuation). The Transaction Valuation set forth above was calculated for the sole purpose of determining the filing fee and should not be used for any other purpose.

Edgar Filing: Regulus Therapeutics Inc. - Form SC TO-I/A

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$86.22

Filing Party: Regulus Therapeutics Inc.

Form or Registration No.: 005-87002

Date Filed: October 15, 2018

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

third party tender offer subject to Rule 14d-1.

issuer tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

---

### Explanatory Note

This Amendment No. 1 to Tender Offer Statement on Schedule TO (this Amendment No. 1) amends and supplements the Tender Offer Statement on Schedule TO (the Schedule TO) relating to the Offer to Exchange Eligible Options for New Restricted Stock Units dated October 15, 2018 (the Exchange Offer) by Regulus Therapeutics Inc., a Delaware corporation (the Company), originally filed by the Company with the Securities and Exchange Commission on October 15, 2018.

On November 9, 2018, the Company filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 (the Q3 10-Q). This Amendment No. 1 is made to (i) amend and restate Item 10(a) (Financial Information) of the Schedule TO to incorporate by reference the Q3 10-Q and to update the book value per share of the Company's common stock, par value \$0.001 per share (the Common Stock) as of September 30, 2018 and (ii) amend and supplement Item 12 (Exhibits) of the Schedule TO to update Exhibit (a)(1)(A) to incorporate by reference the Q3 10-Q, to add the Q3 10-Q as Exhibit (a)(1)(O) and to add the Third Amendment to Loan and Security Agreement, dated August 6, 2018, by and between the Company and Oxford Finance LLC as Exhibit (d)(18).

The information in the Schedule TO, including all schedules and annexes to the Schedule TO, which were previously filed with the Schedule TO, is incorporated herein by reference to answer the items required in this Schedule TO, except that such information is hereby amended and supplemented to the extent specifically provided in this Amendment No. 1. Except as specifically set forth herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule TO.

#### Item 10. Financial Information.

Item 10(a) of the Schedule TO is amended and restated as follows:

(a) *Financial Information.* The information set forth in Item 15 (Exhibits, Financial Statement Schedules) of the Company's Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 8, 2018, which is incorporated herein by reference; the information set forth in Item 1 (Financial Statements) of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the Securities and Exchange Commission on May 10, 2018, which is incorporated herein by reference; the information set forth in Item 1 (Financial Statements) of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, filed with the Securities and Exchange Commission on August 9, 2018, which is incorporated herein by reference; the information set forth in Item 1 (Financial Statements) of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 9, 2018, which is incorporated herein by reference; the financial information contained in the Exchange Offer under Section 8 (Information Concerning Us; Financial Information) including Schedule A to the Exchange Offer; and Section 15 (Additional Information) of the Exchange Offer is incorporated herein by reference. See Section 15 (Additional Information) of the Exchange Offer for more information regarding how to obtain copies of or otherwise review such reports. The book value per share of the Common Stock as of September 30, 2018 was \$0.18 (as adjusted for the 1-for-12 reverse stock split of the Common Stock effective on October 3, 2018).

#### Item 12. Exhibits.

Item 12 of the Schedule TO is amended and supplemented by updating Exhibit (a)(1)(A) and adding a new Exhibit (a)(1)(O) and Exhibit (d)(18) as follows:

#### Exhibit

#### Description

- No.**
- (a)(1)(A) Offer to Exchange Eligible Options for New Restricted Stock Units dated October 15, 2018, as amended on November 9, 2018.
  - (a)(1)(O) Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 9, 2018 and incorporated herein by reference.
  - (d)(18) Third Amendment to Loan and Security Agreement, dated August 6, 2018, by and between the Company and Oxford Finance LLC (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q (File No. 001-35670), filed with the Securities and Exchange Commission on November 9, 2018).

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Regulus Therapeutics Inc.**

By: /s/ Joseph P. Hagan  
Joseph P. Hagan  
President and Chief Executive Officer

Date: November 9, 2018